Clindamycin Equity 150 mg Capsule
PDF Leaflet Revision Date: 23 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Serious infections caused by susceptible organisms.
Dosage (summary)
Adults: 150 mg every 6 hours; Severe: up to 450 mg every 6 hours.
Special Populations
- Elderly patients
- Paediatric population
Pregnancy & Breastfeeding
Safety in pregnancy not established; contraindicated in lactation.
Key Drug Interactions
- Increased bleeding with vitamin K antagonists
- Enhanced neuromuscular blockade
Contraindications
- Hypersensitivity to clindamycin
- Diarrhoeal states
- Gastrointestinal disease
Common side effects
- Diarrhoea
- Abdominal pain
- Eosinophilia
- Maculopapular rash
Counselling Points
- Take with a full glass of water
- Report severe diarrhoea
- Avoid in pregnancy and breastfeeding
Serious warnings
- Severe hypersensitivity reactions
- Risk of antibiotic-associated colitis
Important Disclaimer
The Clindamycin Equity 150 mg Capsule professional information leaflet below is the property of Equity Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
